Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

UNLABELLED: Pre-eclampsia is a complex disease with significant maternal and fetal morbidity and mortality. Its syndromic nature makes diagnosis and management difficult. The field is rapidly evolving with the definition of pre-eclampsia being challenged by some organisations, with proteinuria no longer being essential in the presence of other features. In the last decade, angiogenic factors, in particular soluble fms-like tyrosine kinase 1 (sFlt-1), have emerged as important molecules in the pathogenesis of pre-eclampsia. Here we review the most recent evidence regarding the potential of these factors as biomarkers and therapeutic targets for pre-eclampsia. TWEETABLE ABSTRACT: A review of angiogenic factors, sFlt-1 and PlGF, in the diagnosis, prediction and management of pre-eclampsia.

More information Original publication

DOI

10.1111/1471-0528.15042

Type

Journal article

Publication Date

2018-10-01T00:00:00+00:00

Volume

125

Pages

1389 - 1395

Total pages

6

Keywords

Angiogenic factors, National Institute for Clinical Excellence, fms-like tyrosine kinase 1, placental growth factor, pre-eclampsia, pregnancy, Angiogenesis Inducing Agents, Biomarkers, Female, Humans, Maternal Serum Screening Tests, Pre-Eclampsia, Pregnancy, Vascular Endothelial Growth Factor Receptor-1